Abstracts tagged "ANA"

Abstract Number: 0003 • ACR Convergence 2021
Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection
Richard Ramonell¹, Matthew Woodruff², Mark Rudolph³, F. Eun-Hyung Lee¹ and Iñaki Sanz⁴, ¹Emory University, Atlanta, GA, ²Emory University, Decatur, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…
Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 791 • 2019 ACR/ARP Annual Meeting
Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
May Choi¹, Emily Mirizio ², Fernanda Quinteros ³, Katherine Buhler ⁴, Marvin Fritzler ¹ and Kathryn Torok ⁵, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Pittsburgh, Pittsburgh, ³University of Calgary, Calgary, ⁴University of Calgary, Calgary, Canada, ⁵UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We…
Abstract Number: 265 • 2019 ACR/ARP Annual Meeting
Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline
Pamela Anjara ¹, David Liew², Victor Yang ³, Christopher McMaster ² and Russell Buchanan ³, ¹Austin Hospital, Melbourne, Victoria, Australia, ²Austin Health, Melbourne, Victoria, Australia, ³Austin Health, Heidelberg, Victoria, Australia
Background/Purpose: In October 2017, the Australian Rheumatology Association widely promoted a list of five recommendations on low-value practices to general clinicians and patients as part…
Abstract Number: 306 • 2019 ACR/ARP Annual Meeting
Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders
Jihad Ben Gabr¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: The American College of Rheumatology (ACR) established case definitions of 19 specific neuropsychiatric syndromes seen in patients with systemic lupus erythematosus (SLE) (1). Therefore,…
Abstract Number: 308 • 2019 ACR/ARP Annual Meeting
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Konrad Dziamski¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…
Abstract Number: 790 • 2019 ACR/ARP Annual Meeting
Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Ovgu Kul Cinar¹, Charlene Foley ², Ali Al-Hussain ³, Kimberly Gilmour ⁴, Matthew Buckland ⁴ and Muthana Al-Obaidi ⁵, ¹Great Ormond Street Hospital, Lonodn, United Kingdom, ²Great Ormond Street Hospital, London, Ireland, ³Great Ormond Street Hospital, London, United Kingdom, ⁴Great Ormond Street Hospital NHS Trust, Camelia Botnar Laboratories, London, United Kingdom, ⁵Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
Background/Purpose: Antinuclear antibodies (ANA) are autoantibodies that recognise cellular antigens found predominantly in the cell nucleus. They are associated with numerous autoimmune diseases such as…
Abstract Number: 11 • 2018 ACR/ARHP Annual Meeting
PAD4-Independent Interaction of ACPA with Nuclear Antigens in Apoptotic Cells and Neutrophil Extracellular Traps (NETs) Defines a Subset of Autoantibodies
Gustaf Wigerblad¹, Katy A. Lloyd¹, Peter Sahlström², Karine Chemin², Johanna Steen², Philip J. Titcombe^2,3, Diana Zhou², Ragnhild Stålesen¹, Bianka Marklein⁴, Elena Ossipova², Johan Rönnelid⁵, Luca Piccoli⁶, Antonio Lanzavecchia⁶, Daniel L. Mueller³, Karl Skriner⁴, Lars Klareskog², Fredrik Wermeling¹, Vivianne Malmström² and Caroline Grönwall⁷, ¹Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Dept. of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Università della Svizzera italiana, Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) associated anti-citrullinated protein autoantibodies (ACPA) bind a wide range of citrullinated proteins with high cross-reactivity. Recent findings suggest that certain, but…
Abstract Number: 89 • 2018 ACR/ARHP Annual Meeting
Anti-Nuclear Antibodies (ANA) and Air Pollution: Ultrafine Particles and Ozone
Sasha Bernatsky¹, Shouao Wang², May Y Choi³, Scott Weichenthal⁴, Marianne Hatzopoulou⁵, Marvin J. Fritzler⁶ and Audrey Smargiassi⁷, ¹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada, ⁵Civil and Mineral Engineering, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Public Health, Université de Montreal, Montreal, QC, Canada
Background/Purpose: Previous studies have suggested links between air pollution (particularly PM2.5) and serum antibodies related to rheumatic diseases. No one has yet examined anti-nuclear antibody…
Abstract Number: 98 • 2018 ACR/ARHP Annual Meeting
Presence of Apoptotic Microparticle Containing Immune Complexes in Asymptomatic ANA+ Individuals Despite the Absence of Inflammation
Carolina Muñoz-Grajales^1,2, Dennisse Bonilla¹, Ariana Karanxha¹, Dario Ferri^1,2, Earl Silverman³, Sindhu Johnson⁴, Arthur Bookman⁵, Zahi Touma^5,6 and Joan E. Wither^1,2,5,7, ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Department of Immunology, Department of Immunology, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Division of Rheumatology, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Department of Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Currently, little is known about what distinguishes asymptomatic Anti-Nuclear Antibody (ANA) positive individuals (ANA+NS) who will progress to Systemic Lupus Erythematosus (SLE) from those…
Abstract Number: 110 • 2018 ACR/ARHP Annual Meeting
Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
Miles C. Smith¹, Samantha Slight-Webb¹, Susan R. Macwana¹, Judith A. James^2,3 and Joel M. Guthridge¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine & Pathology, Univ. of Oklahoma, Okla, OK
Background/Purpose: One hallmark of the autoimmune disease Systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While the specificities and levels can indicate…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting
Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus
Meera Tarazi¹, Carolyn Kushner², Rebecca Gaffney² and Victoria P. Werth³, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…

1
2
3
…
5
Next Page »